Omicron News and Research

RSS

Immunological landscape of England during Omicron-driven SARS-CoV-2 wave

In a new study, researchers determined the immunological landscape of England throughout the SARS-CoV-2 Omicron wave.

24 Feb 2022

Edible egg-derived IgY antibodies against SARS-CoV-2 Omicron

A new study posted to the bioRxiv* preprint server reports on the development of anti-RBD immunoglobulin Y (IgY) antibodies from chicken eggs to block the binding of the viral RBD to human ACE2 receptors. This approach has several advantages since chicken egg-derived IgY can be edible and polyclonal can target multiple epitopes, enhancing neutralizing activity.

23 Feb 2022

Study on Omicron related mortality in cancer patients during recent COVID wave

A recent pre-proof study published in the journal Cancer Cell assessed the CFR of cancer patients during the third wave of the coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 Omicron variant.

23 Feb 2022

Study explores the effectiveness of Moderna COVID-19 vaccine against omicron, delta variants

New Kaiser Permanente research published February 21, 2022 in Nature Medicine shows that while Moderna COVID-19 vaccine protection is strong against coronavirus infection by the delta variant, it is not as strong against infection from the omicron variant.

23 Feb 2022

Understanding the immune responses after secondary vaccinations with Pfizer and Moderna vaccines

In a new study, researchers assessed the serological responses to secondary booster doses of Pfizer's Comirnaty and Moderna's Spikevax COVID-19 vaccines.

23 Feb 2022

High nasopharyngeal viral load in SARS-CoV-2 Omicron-induced infection

In a recent study posted to the Research Square* pre-print server, a team of researchers from Italy and the United States (US) retrospectively reviewed and compared viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and previous SARS-CoV-2 strain-induced infection.

23 Feb 2022

More evidence vaccines prevent ICU admission and mortality from SARS-CoV-2

In a recent study posted to the medRxiv* preprint server, researchers estimated the comparative virulence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between the vaccinated and unvaccinated subjects hospitalized with coronavirus disease 2019 (COVID-19) in Canada.

23 Feb 2022

hAELVi cell infection model mimics SARS-CoV-2 Omicron infection in lower respiratory tract of humans

In a recent study posted to the Research Square* preprint server, which is under consideration at Scientific Reports, a team of researchers developed a novel human Alveolar Epithelial Lentivirus immortalized (hAELVi) cell infection model to estimate the replication potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the lower respiratory tract of humans.

23 Feb 2022

SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil

In a recent study posted to the medRxiv* pre-print server, researchers performed genomic monitoring to estimate the magnitude and range of the different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in SARS-CoV-2 reinfection cases among fully vaccinated individuals in Salvador, Bahia, Brazil.

23 Feb 2022

Omicron neutralizing titers after third BNT162b2 dose are persistent

The new study, published in the journal Cell Host and Microbe, also finds that the neutralization against Omicron remains robust at four months after the third dose of the BNT162b2 vaccine.

22 Feb 2022

Study shows Pfizer-BioNTech booster protects over 65s against Delta and Omicron

New research in nursing home residents found that a third dose of the Pfizer-BioNTech COVID-19 vaccine was effective for at least three months in protecting against the Delta and Omicron variant. While two doses of an mRNA COVID-19 vaccine showed poor neutralization to Omicron than Delta, a booster shot increased neutralizing antibody responses.

22 Feb 2022